New Key Publication: The chemotherapeutic drug doxorubicin does not exacerbate p16Ink4a-positive senescent cell accumulation and cardiometabolic disease development in young adult female LDLR-deficient mice
Highlights
- Doxorubicin treatment induces acute gonadal white adipose tissue inflammation.
- DOX does not induce p16Ink4a+-senescent cells in young adult female Ldlr−/−-p16-3MR mice.
- DOX treatment results in a long-term reduction in gonadal white adipose tissue mass.
- Long-term cardiometabolic health in young adult female HFC-diet-fed mice is not affected by DOX.
- Clearance of p16Ink4a+-senescent cells does not improve diet-induced atherosclerosis.
Authors:
- Andrea C Postmus
- Janine K Kruit
- Roos E Eilers
- Rick Havinga
- Mirjam H Koster
- Yoshikazu Johmura
- Makoto Nakanishi
- Bart van de Sluis
- Johan W Jonker
Read more: Toxicology and Applied Pharmacology: https://www.sciencedirect.com/science/article/pii/S0041008X23001709?via%3Dihub
| Last modified: | 24 April 2023 10.05 a.m. |
More news
-
16 April 2024
UG signs Barcelona Declaration on Open Research Information
In a significant stride toward advancing responsible research assessment and open science, the University of Groningen has officially signed the Barcelona Declaration on Open Research Information.
-
02 April 2024
Flying on wood dust
Every two weeks, UG Makers puts the spotlight on a researcher who has created something tangible, ranging from homemade measuring equipment for academic research to small or larger products that can change our daily lives. That is how UG...
-
18 March 2024
VentureLab North helps researchers to develop succesful startups
It has happened to many researchers. While working, you suddenly ask yourself: would this not be incredibly useful for people outside of my own research discipline? There are many ways to share the results of your research. For example, think of a...